February 2026 in “ACS Omega” This study developed a multifunctional hydrogel, QTMP-Gel, which significantly accelerated wound healing in an oral mucositis hamster model by providing antioxidant and antibacterial effects, reducing inflammation, and controlling infection.
April 2010 in “Cancer Research” This study suggests that Mcl-1 has a non-apoptotic role in promoting keratinocyte proliferation and Wnt/β-catenin signaling, potentially indicating a novel oncogenic activity.
6 citations
,
January 2015 in “Journal of clinical & experimental dermatology research” This study suggests that combining monoammonium glycyrrhizinate/glycine/DL-methionine tablets with 5% carpronium chloride may reduce alopecia areata area more effectively than carpronium chloride alone, particularly in patients with allergic factors.
August 2009 in “Mechanisms of Development”
24 citations
,
May 2013 in “Drug Design Development and Therapy” This pilot study found that a multimodal minoxidil microemulsion with diclofenac and tea tree oil was more effective and safer than minoxidil alone for treating androgenic alopecia over 32 weeks.
19 citations
,
June 2010 in “Journal of acupuncture and meridian studies” This study found that emodin from Polygonum multiflorum showed 5alpha-reductase inhibitory activity, which was more potent than alizarin but less potent than riboflavin.
324 citations
,
May 2002 in “Oncogene” May 2026 in “Journal of Assisted Reproduction and Genetics” In this study, researchers developed and tested a novel peptide, AMHR2BP, which mimics the function of Anti-Müllerian hormone to protect ovarian follicles in mice, showing promise for preserving ovarian health during chemotherapy without causing toxicity.
3 citations
,
July 2015 in “Australasian Journal of Dermatology” This letter discusses a case of iododerma in pregnancy linked to iodinated multivitamin use, but reports no new clinical findings.
19 citations
,
July 1997 in “British Journal of Dermatology” This study successfully developed and characterized a monospecific monoclonal antibody, LHTric-1, that specifically localizes to the pre-cortical region of the hair follicle and can aid research on hair and nail formation.
September 2017 in “PubMed” In this case report, a Danish family with monilethrix showed varying symptoms, diagnosed via dermatoscopy, microscopy, and gene sequencing. The study highlights that while no cure exists, oral minoxidil shows promise in a single case, and reducing hair trauma remains key for management.
10 citations
,
July 2014 in “Annals of Saudi Medicine” This case report describes a rare concurrence of Morbihan disease with eyelid edema and extrafacial lupus miliaris disseminatus faciei in a patient, noting improvement of truncal lesions with roxithromycin and resolution of eyelid edema following surgical treatment.
3 citations
,
May 2021 in “Archiv der Pharmazie” This study found that the FGF-2 mimetic SUN11602 and VEGF mimetic ONO-1301 had unique effects on skin fibroblasts and keratinocytes, indicating potential for improving wound healing.
30 citations
,
January 2024 in “Frontiers in Pharmacology” This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.
January 2022 in “Drugs of Today” 26 citations
,
October 1998 in “Experimental Dermatology” This study describes a co-dominant E410D mutation in keratin hHb6 associated with severe hair loss and extensive papules in homozygous individuals, with variable expression in heterozygous family members.
5 citations
,
February 2022 in “Molecular genetics & genomic medicine” This study identified genetic variants in the DSG4 gene associated with the autosomal recessive form of monilethrix in Chinese patients, expanding the understanding of its phenotypic spectrum and clinical features.
1 citations
,
December 2007 in “Journal of Microbiology and Biotechnology” This study found that Minoxidil included in triamino alpha-cyclodextrin significantly promoted hair growth in mice, potentially due to its enhanced substantivity on skin.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” This review discusses the pharmacological profile of teriflunomide for treating relapsing multiple sclerosis, highlighting its safety and effectiveness in reducing relapses and slowing disability progression, though direct comparisons with other oral medications are lacking.
4 citations
,
July 2022 in “The Journal of Clinical Endocrinology & Metabolism” This study identified a novel homozygous mutation in the 5'-UTR of the POMC gene, suggesting a new molecular mechanism for the syndrome of adrenal insufficiency, obesity, and red hair.
6 citations
,
March 2017 in “Journal of the European Academy of Dermatology and Venereology” This article reviews genetic mutations linked to monilethrix, a hereditary hair disorder, and reports no new clinical findings on the condition's variability in symptoms and severity.
32 citations
,
January 2000 in “Human Heredity” This study found that the mutation Glu402Lys in keratin hHb6 may be associated with monilethrix, and homozygous patients in a consanguineous family exhibited more severe symptoms.
97 citations
,
December 2011 in “New England Journal of Medicine” This article discusses the FDA's decision not to approve 5α-reductase inhibitors for prostate cancer prevention, citing an increase in high-grade tumors but no mortality evidence, and reports no new results.
10 citations
,
September 1997 in “Molecular carcinogenesis” This study found that mirex and TPA promote papilloma formation in CD-1 mouse skin through distinct populations of mutant Ha-ras cells, resulting in additive tumor yields.
5 citations
,
September 2013 in “BMB Reports” In this study, the anti-wrinkle effect of bone morphogenetic protein receptor 1a extracellular domain was significantly greater than that of retinoic acid in a mouse model, suggesting potential for BMP antagonists in skin or hair treatments.
20 citations
,
December 2016 in “Neurodegenerative disease management” This study found that teriflunomide, an oral medication taken once daily, significantly slowed disability progression in patients with relapsing multiple sclerosis, supported by positive results in two Phase III trials and supplemented by various analyses including long-term studies and patient-reported outcomes.
March 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly”